PB1933 CLINICAL FEATURES AND TREATMENT OUTCOMES OF CHRONIC PHASE‐CHRONIC MYELOID LEUKEMIA PATIENTS IN TURKEY: REAL‐WORLD DATA

Background: Tyrosine kinase inhibitors (TKIs) have been standard‐of‐care for patients with chronic myeloid leukemia (CML) and improvements with TKIs have been obtained in survival rates. In Turkey, imatinib is the only reimbursed TKI for first line treatment and second generation TKI's are reserved for later lines. Some concerns such as TKI tolerability, adverse event profile, patient comorbidities, and concomitant drug use may affect the choice...